Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan

详细信息    查看全文

• 作者：Kenji Hosoi ; Yoshikazu Ohtsuka ; Tohru Fujii ; Takahiro Kudo ; Nobuaki Matsunaga ; Takeshi Tomomasa ; Hitoshi Tajiri ; Reiko Kunisaki ; Takashi Ishige ; Hiroyuki Yamada ; Katsuhiro Arai ; Atsushi Yoden ; Kosuke Ushijima ; Tomoki Aomatsu ; Satoru Nagata ; Keiichi Uchida ; Kazuo Takeuchi and Toshiaki Shimizu
• 刊名：Journal of Gastroenterology and Hepatology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：32
• 期：1
• 页码：114-119
• 全文大小：301K
• ISSN：1440-1746

文摘

Childhood-onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporin (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long-term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan. Additionally, we assessed IFX use in pediatric patients with Crohn's disease (CD).